220 related articles for article (PubMed ID: 25807961)
1. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
Schwarz J; Ovesná P; Černá O; Kissová J; Maaloufová Soukupová J; Brychtová Y; Doubek M; Červinek L; Cmunt E; Dulíček P; Campr V; Křen L; Penka M;
Eur J Haematol; 2016 Jan; 96(1):98-106. PubMed ID: 25807961
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
3. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
4. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
5. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
6. Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.
Buxhofer-Ausch V; Steurer M; Sormann S; Schloegl E; Schimetta W; Gisslinger B; Ruckser R; Gastl G; Gisslinger H
Eur J Haematol; 2016 Dec; 97(6):511-516. PubMed ID: 27037858
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
Petrides PE; Gisslinger H; Steurer M; Linkesch W; Krumpl G; Schüller A; Widmann R
Clin Ther; 2009 Feb; 31(2):386-98. PubMed ID: 19302911
[TBL] [Abstract][Full Text] [Related]
8. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide: 20 years later.
Emadi A; Spivak JL
Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
[TBL] [Abstract][Full Text] [Related]
10. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
11. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Michiels JJ
Pathol Biol (Paris); 2003 Apr; 51(3):167-75. PubMed ID: 12781799
[TBL] [Abstract][Full Text] [Related]
12. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
13. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Gugliotta L; Iurlo A; Gugliotta G; Tieghi A; Specchia G; Gaidano G; Scalzulli PR; Rumi E; Dragani A; Martinelli V; Santoro C; Randi ML; Tagariello G; Candoni A; Cattaneo D; Ricco A; Palmieri R; Liberati MA; Langella M; Rago A; Bergamaschi M; Monari P; Miglio R; Santoro U; Cacciola R; Rupoli S; Mastrullo L; Musto P; Mazzucconi MG; Vignetti M; Cortelezzi A; Vianelli N; Martino B; De Stefano V; Passamonti F; Vannucchi AM;
Leuk Res; 2016 Jul; 46():18-25. PubMed ID: 27107744
[TBL] [Abstract][Full Text] [Related]
14. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
15. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
Kissova J; Bulikova A; Ovesna P; Bourkova L; Penka M
Int J Hematol; 2014 Nov; 100(5):429-36. PubMed ID: 25227185
[TBL] [Abstract][Full Text] [Related]
16. [An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients].
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Udvardy M; Karádi É; Kellner Á; Egyed M
Orv Hetil; 2017 Jan; 158(3):111-116. PubMed ID: 28110571
[TBL] [Abstract][Full Text] [Related]
17. [Primary thrombocythemia: diagnosis and therapy].
Petrides PE
Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Kellner A; Dombi P; Illes A; Demeter J; Homor L; Ercsei I; Simon Z; Karadi E; Herczeg J; Gy Korom V; Gasztonyi Z; Szerafin L; Udvardy M; Egyed M
Eur J Haematol; 2020 Oct; 105(4):408-418. PubMed ID: 32557810
[TBL] [Abstract][Full Text] [Related]
19. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
Marchetti M; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
[TBL] [Abstract][Full Text] [Related]
20. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]